InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference
December 23, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025, in San Francisco. CEO Robert Eno and CFO Timothy Cruickshank will meet with investors and potential partners to discuss the recently FDA-cleared HeartBeam system, the first cable-free, credit card-sized […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA Clearance for Innovative Arrhythmia Assessment Device
December 16, 2024
HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its groundbreaking HeartBeam system, a credit card-sized, cable-free ECG device designed for comprehensive arrhythmia assessment. The system enables patients to record high-fidelity heart signals from three directions during symptoms, with data transmitted to physicians for timely review and action. This milestone marks the first FDA-cleared device […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Technology at AHA Conference
November 19, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add to the body of evidence for HeartBeam’s key clinical indications, specifically arrhythmia and heart attack […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Cardiac Care Technology with FDA Submissions and Key Leadership Appointments
November 8, 2024
HeartBeam (NASDAQ: BEAT), reported steady progress in its third quarter financial and operational results, advancing its cardiac care technology through key FDA 510(k) submissions and strategic leadership appointments. The company’s first FDA 510(k) submission for the HeartBeam system is actively under review, with HeartBeam responding to FDA inquiries and preparing for an Early Access Program […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 Earnings Call with Key Regulatory and Initiative Updates
October 31, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on enhancing cardiac care through advanced insights, will hold a conference call on November 7, 2024, at 4:30 p.m. ET to discuss third-quarter results and share updates on regulatory developments and ongoing projects. CEO Robert Eno, Founder and President Dr. Branislav Vajdic, and CFO Timothy Cruickshank will […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2024 Digital Health Hub Award for Innovation in Cardiac Care
October 24, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic’ category at the HLTH global healthcare conference. The award highlights HeartBeam’s innovative vector-based technology, which captures heart electrical signals in three dimensions to provide detailed cardiac insights. […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Robert Eno as New CEO to Lead Next Phase of Growth and Innovation
October 17, 2024
HeartBeam (NASDAQ: BEAT) has appointed Robert Eno as its new chief executive officer, effective Oct. 21, 2024. Eno, who joined the company as President in January 2023, will focus on guiding HeartBeam through FDA 510(k) clearance and preparing for commercialization of its transformative vector-based cardiac technology. Founder and current CEO, Dr. Branislav Vajdic, will transition […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist
September 24, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial intelligence (“AI”) scientist: Lance Myers, PhD. According to the announcement, Myers is the former head of data science at Verily, formerly Google Life Sciences. A renowned industry leader […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Industry Expert as New CFO
September 10, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has named a seasoned medtech leader as its new chief financial officer. According to the announcement, Timothy Cruickshank has accepted the role of chief financial officer, effective immediately; he succeeds Richard Brounstein, who announced his retirement. Cruickshank […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update
August 15, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Conference Call, Webcast to Discuss Q2 Results
August 1, 2024
HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin at 4:30 p.m. ET on Aug. 14, 2024. HeartBeam executives, including Branislav Vajdic, CEO and […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Now Listed on Russell Microcap Index
July 1, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconstitution. According to the announcement, the annual Russell U.S. Indexes represent […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Positive Study Data for Its AI Program
May 20, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter. Key findings from the analysis show that HeartBeam AI […]
InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) AIMIGo(TM) Recognized as ‘Best New ECG Technology Solution’ in Awards Program
May 13, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that its HeartBeam AIMIGo(TM) was selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. Conducted by MedTech Breakthrough, an independent market intelligence organization, the awards […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2024 Financial, Operational Report
May 10, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on its financial and operational results for first quarter 2024, for the period ended March 31, 2024. Highlights of the report include the 510(k) submission for BEAT’s AIMIGo(TM) system for review by the U.S. Food […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Conference Call to Discuss Q1 2024 Results
April 25, 2024
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced that it will hold a conference call on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Key Data in First-Ever Scientific Presentation of Proprietary HeartBeam AI
April 9, 2024
HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is presenting new data at the European Heart Rhythm Association (“EHRA”) Conference. According to the announcement, this is the first scientific presentation on the company’s deep learning algorithm: HeartBeam AI. The data demonstrates that applying the company’s artificial […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023
March 21, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System
March 14, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Awarded Two New US Patents Covering Core Cardiac Monitoring Technology
March 7, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the United States Patent and Trademark Office. The two new patents bring the total of issued patents in HeartBeam’s portfolio to […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call
March 5, 2024
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combines AI, Proprietary Technology to Deliver Unprecedented Cardiac Insights
December 14, 2023
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (“AI”) applied to its proprietary vectorelectrocardiography (“VECG”) technology, as well as new leadership and advisory roles. By coupling machine learning methods with its VECG technology, HeartBeam aims […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2023 Financial Report, Operational Update
November 15, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting its financial and operational results for the third quarter ended Sept. 30, 2023. Highlights of the report […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Scientific Advisory Board as It Advances Product Development, Clinical and Commercial Efforts
November 9, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced the expansion of its scientific advisory board (“SAB”) to include several leading cardiologists. New members include Charles L. Brown III, MD, CEO of the Piedmont Healthcare Physician Enterprise, […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Granted 3rd US Patent on Novel VECG Platform
November 7, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced that the United States Patent and Trademark Office has granted a new patent on its VECG platform. Patent number 11,793,444, “Electrocardiogram Patch Devices and Methods,” describes methods and […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Third Quarter 2023 Results Conference Call
October 31, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday, Nov. 14, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended Sept. 30, 2023. […]
Dawson James Small Cap Growth Conference: Exploring a Changing World of Investment Opportunities
September 26, 2023
Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Conference to be held in Wyndham Grand Harborside Jupiter, Jupiter, FL, October 12, 2023. The distinguished conference serves as a hallmark in the financial world, featuring important management experts slated to […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Leaders to New Senior Management Positions
September 26, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has appointed two new team leaders. The company announced that Richa Gujarati will serve as senior vice president over product, and […]
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
September 21, 2023
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2023 Financial Report, Corporate Update
August 11, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second quarter ended June 30, 2023. Highlights of the report include the closing of a $25 million secondary offering and $1.5 […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces First Peer-Reviewed Publication Based on Its VECG Technology
August 9, 2023
HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Deborah Castillo to Lead Regulatory Strategy and Execution
August 8, 2023
HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced its appointment of Deborah Castillo, PhD, as vice president of regulatory affairs. An experienced biomedical engineer […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q2 2023 Results Call, Webcast
July 27, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced that it will hold a conference call to discuss its results for the second quarter ended June 30, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Physician, Researcher to Board of Directors
July 26, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors: Michael R. Jaff, DO. This appointment brings the number of board members to eight. A renowned vascular physician and researcher, […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Wealth of Expertise to Its Board with Appointments of Ken Nelson and Mark Strome
June 8, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced the appointment of Ken Nelson and Mark Strome to its board of directors, effective as of June 5, 2023. Nelson is a 20-year digital health, medical device and remote […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Enters SAA with Samsung
May 30, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced its entry into a strategic alliance agreement (“SAA”) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired LIVMOR assets earlier this year. Under the agreement, […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Granted Key Patent for Use in Innovative System Designed to Help Evaluate Cardiac Symptoms
May 25, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution
May 18, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its HeartBeam AIMIGo(TM) System. The HeartBeam AIMIGo System is a personal, portable and […]
InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2023 Financial Report, Corporate Updates
May 12, 2023
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the first quarter 2023, the period ended March 31, 2022. Key takeaways from the report include that the company closed on a $26.5million […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes $25M Capital Raise to Achieve Upcoming Milestones, Extend Cash Runway
May 3, 2023
HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions. The company today announced the closing of its secondary offering of 16,666,666 shares of HeartBeam’s common stock. According to the […]